| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
3 companies
Takeda Pharmaceutical Co Ltd is a 10% Owner at OVID, with reported holdings spanning 3 companies. Recent filings cover 1 purchase and 51 sales. Those positions are worth an estimated $30.4M at current prices.
Our model assigns Takeda Pharmaceutical Co Ltd a strong insider score of 70/100, based on 40 past trades. Over a 12-month horizon, 87.5% of those trades were profitable, with an average 12-month return of +9.9%.
Takeda Pharmaceutical Co Ltd's largest disclosed position is in PHAT as 10% Owner, worth about $30.4M. The recent filings there lean toward selling, a net 4,916,417 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2021 | PHAT Phathom Pharmaceuticals, Inc. | 10% Owner | Sell | 7,138 | $35.14 | $250,803.06 | -0.7% | - | - | |
| May 4, 2021 | PHAT Phathom Pharmaceuticals, Inc. | 10% Owner | Sell | 33,992 | $37.00 | $1,257,848.68 | -3.1% | -11.3% | -62.1% | |
| Oct 8, 2019 | OVID Ovid Therapeutics Inc. | 10% Owner | Buy | 2,000,000 | $2.50 | $5,000,000.00 | +53.3% | - | - |